Royal Bank Of Canada Avrobio, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$1.15 - $1.48 $2,176 - $2,801	1,893 New	1,893 $2,000
Q4 2023 Feb 14, 2024	SELL	$1.22 - $1.62 $104 - $139	-86 Reduced 4.35%	1,893 $2,000
Q3 2023 Nov 14, 2023	SELL	$0.98 - $1.62 $339 - $560	-346 Reduced 14.88%	1,979 $3,000
Q2 2023 Aug 14, 2023	BUY	$0.58 - $1.31 $266 - $602	460 Added 24.66%	2,325 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $0.91 $250 - $356	-392 Reduced 17.37%	1,865 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.68 - $1.11 $205 - $335	302 Added 15.45%	2,257 $1,000
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $1,677 - $2,975	-2,237 Reduced 53.36%	1,955 $2,000
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $6,769 - $21,201	-5,248 Reduced 55.59%	4,192 $5,000
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $12,409 - $21,761	3,597 Added 61.56%	9,440 $36,000
Q3 2021 Nov 15, 2021	SELL	$5.53 - $9.28 $4.6 Million - $7.73 Million	-832,705 Reduced 99.3%	5,843 $32,000
Q2 2021 Aug 16, 2021	BUY	$7.84 - $12.6 $6.57 Million - $10.6 Million	838,548 New	838,548 $7.46 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.